Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome - Scorecard - MDSpire
Advertisement
Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome
Clinical Scorecard: Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome
At a Glance
Category
Detail
Condition
Acute Coronary Syndrome in Diabetic Patients
Key Mechanisms
Dual antiplatelet therapy (DAPT) reduces stent thrombosis risk but increases bleeding risk proportional to treatment duration.
Target Population
Diabetic patients with Acute Coronary Syndrome undergoing PCI
Care Setting
Interventional cardiology, outpatient follow-up
Key Highlights
DAPT reduces major adverse cardiovascular events (MACE) but increases bleeding risk.
Study compares 3 months of DAPT followed by ticagrelor monotherapy versus 12 months of DAPT.
400 diabetic patients were randomized for the study.
Guideline-Based Recommendations
Diagnosis
Assessment of cardiovascular risk factors and symptoms in diabetic patients.
Management
Initiate DAPT with aspirin and ticagrelor post-PCI for 3 months, then consider monotherapy.
Monitoring & Follow-up
Regular follow-up for bleeding events and MACE every 3 months.
Risks
Increased bleeding risk associated with prolonged DAPT.
Patient & Prescribing Data
Diabetic patients aged 18-80 with ACS undergoing PCI.
Ticagrelor monotherapy may be considered after 3 months of DAPT to reduce bleeding risk.
Clinical Best Practices
Conduct thorough risk assessment for bleeding before initiating DAPT.
Ensure regular monitoring of patients for MACE and bleeding events.
